Hyerim Lee, Ph.D., is the senior director of translational medicine at HiberCell.
Prior to HiberCell, she was senior director of translational science at Daichi Sankyo, Inc., where she was responsible for developing and implementing translational strategies in its antibody drug conjugate franchise. Before that, she served as global biomarker and diagnostics leader at Merck, where she was responsible for leading medical affairs strategy and execution for gastrointestinal and MSI-H indications for Keytruda. Previously, she oversaw and managed the translational science programs and consortia at The Children’s Tumor Foundation in New York. She has authored or co-authored multiple publications, conference presentations and several patents.
Hyerim earned her Ph.D. in biophysical chemistry at Columbia University and completed a postdoctoral fellowship in cancer biology at Sandford-Burnham Medical Research Institute in San Diego.